Ionis Pharmaceuticals expands revenue with new drug launches and partnerships despite cash burn.

Ionis Pharmaceuticals is advancing its genetic medicine pipeline with new independent U.S. launches of drugs like ZANVASTRO and TRYNGOLZA, which has an expanded indication boosting revenue potential. The company also benefits from partner royalties and diversified pipeline assets such as DAWNZERA and HIBSAGO. Despite ongoing cash burn, Ionis appears to have sufficient financing to reach breakeven, making it a viable long-term investment for patient investors in the biotech sector.

Ionis Pharmaceuticals shares are trading near their 52-week low at USD 42.93 on Pluang, down 2.23% in the last day. The stock's market cap stands at $7.13 billion with a typical hold time of 11 days as of Oct 26, 2026 02:11 WIB.